AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Rhea-AI Summary

AtaiBeckley (NASDAQ: ATAI) said its common stock was added to the NASDAQ Biotechnology Index (NBI), effective prior to market open on Dec 22, 2025. The company cited progress in 2025 including approximately $300 million of capital raised, advancement of multiple clinical programs toward late‑stage development, a strategic combination between atai Life Sciences and Beckley Psytech, and an expected U.S. corporate domiciliation around year‑end.

The NBI tracks Nasdaq‑listed biopharma securities meeting market‑cap, trading volume, and seasoning criteria and is selected annually in December; inclusion can increase visibility among index funds and institutional investors.

Positive

• $300 million capital raise completed in 2025
• Added to the NASDAQ Biotechnology Index (NBI) effective Dec 22, 2025
• Advanced multiple clinical programs toward late‑stage development
• Completed strategic combination between atai Life Sciences and Beckley Psytech

Negative

• None.

Key Figures

Capital raised 2025 approximately $300 million Balance sheet strengthening referenced by CEO for 2025

Q3 2025 revenue $749 thousand Q3 2025 Form 10-Q total revenue

Q3 2025 operating expenses $29.2 million Q3 2025 Form 10-Q operating expenses

Q3 2025 net loss $61.1 million Q3 2025 Form 10-Q net loss

YTD 2025 revenue $3.023 million Year-to-date 2025 revenue from Form 10-Q

YTD 2025 net loss $115.3 million Year-to-date 2025 net loss from Form 10-Q

Shares outstanding 363,190,522 Shares outstanding as of November 10, 2025

NBI effective date December 22, 2025 Date ATAI added to Nasdaq Biotechnology Index

Market Reality Check

$4.33 Last Close

Volume Volume 4,510,853 is 1.38x the 20-day average, indicating elevated trading interest ahead of the NBI addition. normal

Technical Price $4.30 is trading above the 200-day MA at $3.36, reflecting an established upswing prior to index inclusion.

Peers on Argus

ATAI gained 8.59%, outpacing biotech peers like QURE (+5.98%), SYRE (+3.86%), and RAPP (+3.40%), while VERV was slightly negative (-0.09%), pointing to a stock-specific reaction to the NBI news.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 11	Patent grant	Positive	+2.1%	New U.S. patent for EMP-01 with exclusivity protection through 2043.
Nov 19	Leadership changes	Neutral	-4.2%	Executive and board reshuffle to reinforce leadership structure.
Nov 13	Conference participation	Neutral	-4.6%	Announcement of participation in a major healthcare investor conference.
Nov 12	Earnings & updates	Positive	-2.3%	Q3 results plus Breakthrough Therapy designation and financing milestones.
Nov 10	Clinical data	Positive	-0.2%	Positive Phase 2b OLE data for BPL-003 in treatment-resistant depression.

Pattern Detected

Recent positive clinical and corporate updates have often produced modest or even negative next-day moves, suggesting a history of muted or fading reactions to good news.

Recent Company History

Over the last few months, AtaiBeckley has reported several key milestones. A new U.S. patent for EMP-01 with protection to 2043 and positive Phase 2b OLE data for BPL-003 supported its mental health pipeline. Q3 2025 results highlighted Breakthrough Therapy designation, a public offering of about $150 million, and liquidity extending into 2029. Despite these developments, share reactions around prior news were generally modest, making today’s index-addition move comparatively strong.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-29

The company has an effective S-3ASR filed on September 29, 2025, registering securities for resale and allowing flexible offerings, with at least 3 prospectus supplements (including 424B5 and 424B7) already filed, indicating active use of this registration.

Market Pulse Summary

This announcement underscores AtaiBeckley’s progress by securing inclusion in the Nasdaq Biotechnology Index, which requires meeting criteria like minimum market capitalization and average daily trading volume. It follows a year marked by capital raising of approximately $300 million and pipeline advances. Investors may track future index-related ownership changes, the company’s use of its effective S-3ASR, and upcoming clinical and regulatory milestones for BPL-003 and EMP-01.

Key Terms

NASDAQ Biotechnology Index financial

"its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI)"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

Nasdaq financial

"The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

Industry Classification Benchmark financial

"classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB)"

A standardized system that groups companies into industries and sectors based on their main business activities, like a library catalog that puts similar books together. It matters to investors because it enables fair comparisons between peers, guides portfolio construction and sector allocation, determines which stocks belong in industry indexes or ETFs, and helps track industry-level risks and performance trends.

modified capitalization-weighted methodology technical

"The NBI is calculated under a modified capitalization-weighted methodology"

A modified capitalization-weighted methodology is a way of building a stock index that starts with companies sized by market value but then adjusts those weights to avoid any one firm dominating the index or to reflect additional considerations like tradability or sector balance. For investors, it matters because the adjustments change exposure and risk compared with a pure market-cap index — think of it as giving big players somewhat less voting power at a meeting so the outcome better represents the whole room.

AI-generated analysis. Not financial advice.

NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025.

“2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs toward late-stage development, deepened our leadership in next-generation mental health therapeutics through the strategic combination between atai Life Sciences and Beckley Psytech, and are looking forward to the corporate domiciliation to the U.S expected around year end” said Srinivas Rao, Chief Executive Officer of AtaiBeckley. “As we look ahead, AtaiBeckley is entering a pivotal phase and is well positioned to translate scientific leadership into long-term value for both patients and shareholders, as our recent addition to the NBI further validates.”

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market^® (Nasdaq^®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is calculated under a modified capitalization-weighted methodology. Companies in the NBI must meet certain eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

The NBI is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. For more information about the NBI, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Atai Beckley N.V.

AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. It was formed through the strategic combination of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable, and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: the potential benefits of the strategic combination; our business strategy and plans; the timing and potential benefits of the redomiciliation; statements regarding our inclusion in the Nasdaq Biotechnology Index; the potential, success and timing of development and progress of trials and related milestones of our product candidates; and the plans and objectives of management for future operations, research and development and capital expenditures.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in AtaiBeckley’s other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information
Investor Contact:
IR@ataibeckley.com

Media Contact:
PR@ataibeckley.com

FAQ

When was AtaiBeckley (ATAI) added to the Nasdaq Biotechnology Index (NBI)?

AtaiBeckley was added to the NBI effective prior to market open on Dec 22, 2025.

How much capital did AtaiBeckley (ATAI) raise in 2025?

The company raised approximately $300 million during 2025.

What does inclusion in the NBI mean for ATAI shareholders?

NBI inclusion can increase visibility to index funds and institutional investors, potentially boosting demand for ATAI shares.

What corporate changes did AtaiBeckley announce for year‑end 2025?

The company expects a U.S. corporate domiciliation around year‑end 2025.

Did AtaiBeckley report progress on clinical programs in 2025?

Yes; the company said it advanced multiple clinical programs toward late‑stage development in 2025.

How is the Nasdaq Biotechnology Index (NBI) selected and calculated?

Nasdaq selects NBI constituents annually in December; the index uses a modified capitalization‑weighted methodology with market‑cap, trading volume, and seasoning eligibility requirements.